Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jingruo Xia"'
Autor:
Jiajing Cai, Jingruo Xia, Jiang Zou, Qiang Wang, Qiang Ma, Ru Sun, Hebin Liao, Lei Xu, Dongsheng Wang, Xiaolan Guo
Publikováno v:
FEBS Open Bio, Vol 10, Iss 4, Pp 535-545 (2020)
Nearly half of human cancers harbor p53 mutations, and mutant p53 (mutp53) promotes carcinogenesis, metastasis, tumor recurrence and chemoresistance. mutp53 is observed in 30% of breast carcinomas, including triple‐negative breast cancer (TNBC), an
Externí odkaz:
https://doaj.org/article/356d2078fb6546839f8bf6eb345f59ab
Autor:
Qian Liu, Jingruo Xia, Qingtao Yu, Pengcheng Gu, Yue Yuan, Ke Liu, Chaowang Huang, Chunfa Chen, Xiaolan Guo, Hang Qian
Publikováno v:
Macromolecular Bioscience. 22:2200248
Self-assembled DNA nanostructures hold great potentials in biomedical applications. Nevertheless, the negatively charged DNA backbone and susceptivity to enzyme degradation pose challenges to this regard. Engineering the surface properties of DNA nan
Autor:
Lei Xu, Jingruo Xia, Yan Cai, Qiang Ma, Xiaolan Guo, Jiang Zou, Lihua Yao, Hebin Liao, Jiajing Cai, Ru Sun, Xiaowu Zhong, Guangcheng Huang
Publikováno v:
BMB Reports
Dihydroartemisinin (DHA) has been reported to possess anti-cancer activity against many cancers. However, the pharmacologic effect of DHA on HBV-positive hepatocellular carcinoma (HCC) remains unknown. Thus, the objective of the present study was to
Autor:
Jingruo Xia, Jiang Zou, Dongsheng Wang, Lei Xu, Qiang Wang, Hebin Liao, Ru Sun, Qiang Ma, Xiaolan Guo, Jiajing Cai
Publikováno v:
FEBS Open Bio
FEBS Open Bio, Vol 10, Iss 4, Pp 535-545 (2020)
FEBS Open Bio, Vol 10, Iss 4, Pp 535-545 (2020)
Nearly half of human cancers harbor p53 mutations, and mutant p53 (mutp53) promotes carcinogenesis, metastasis, tumor recurrence and chemoresistance. mutp53 is observed in 30% of breast carcinomas, including triple‐negative breast cancer (TNBC), an
Autor:
Jingruo Xia, Yan Cai, Lei Xu, Chang Liu, Xiaolan Guo, Jingdong Li, Qiang Ma, Hebin Liao, Jiang Zou, Ru Sun, Dan Xiao
Publikováno v:
Cancer Research. 78:341-341
Hepatocellular carcinoma (HCC) is a worldwide malignancy. To date, surgery is still the most effective treatment with curative potential, but only about 20% of patients with HCC are eligible for surgical intervention. Therefore exploring the pathogen